CHICAGO — A federal judge declined to certify a class, but denied Pfizer summary judgment on claims it charged more for Maximum Strength Robitussin cough syrup than for Regular Strength Robitussin, when the former had a lower concentration of active ingredients than the latter.
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.

